uniQure Announces Pricing of Upsized $225 Million Public Offering
uniQure N.V. (Nasdaq: QURE) priced an upsized underwritten public offering of 4,945,055 ordinary shares at $45.50 per share, expecting about $225 million in gross proceeds before underwriting and expenses. The company granted a 30-day option for up to 741,758 additional shares. The offering is expected to close around June 25, 2026.
How this was made
The 30-second read
Why it matters
The offering’s fixed price ($45.50), share count, and upsized gross proceeds ($~225M) create a clear dilution/supply overhang into the June 25 close, while also improving funding visibility.
Market read
A priced, upsized follow-on equity raise with a defined close date is a direct catalyst for short-term trading in QURE.
What to watch
Watch for how the company frames use of proceeds in the final prospectus supplement; also consider whether the offering price implies a discount to recent trading levels (not provided here).
Background
uniQure announced and then priced an underwritten public offering under an automatically effective shelf registration statement.
Ticker impact
uniQure priced an upsized $225M public offering of 4,945,055 shares at $45.50, with a 30-day option for 741,758 more.
Likely near-term pressure or volatility around the offering/closing window, with direction depending on whether proceeds are viewed as funding growth vs. balance-sheet relief.
This is a primary capital-raise disclosure with hard terms (price, size, share count, option) and an expected close date, which typically drives dilution expectations and short-term supply-demand effects.
Market effects
Gene therapy peers may see read-across on financing conditions and appetite for equity raises in rare-disease biotech.
Limited direct regional impact; primarily US-listed biotech capital markets flow.
Moderate—global investors in biotech may reassess risk appetite for gene-therapy equity issuance.
Counterpoint
If investors view the proceeds as enabling near-term clinical/commercial milestones, the offering could be digested quickly and support a rebound post-close.
Key entities
- issueruniQure N.V.
Nasdaq-listed gene therapy company pricing an upsized public offering.
- transaction_partiesUnderwriters (Leerink Partners, Stifel, Guggenheim Securities, RBC Capital Markets)
Joint bookrunning managers for the offering; H.C. Wainwright is lead manager.
